The SURPASS 1 through 5 studies were phase 3 clinical trials in which researchers compared the efficacy of 5, 10, or 15 mg tirzepatide with placebo, 1 mg semaglutide, insulin degludec, or insulin ...

Previously, the SURPASS-5 trial compared tirzepatide or placebo plus insulin glargine. Similarly, all three doses of tirzepatide -- 5, 10, or 15 mg -- yielded significantly greater HbA1c ...

The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine (a long-acting insulin) for type 2 diabetes (T2D).

In SURPASS-SWITCH, participants included 282 patients with T2D and baseline A1c 7% to < 9.5% (mean, 7.82%) on either 0.75 mg or 1.5 mg of once-weekly dulaglutide for at least 6 months.

Switching to tirzepatide also led to a weight loss of 10.5 kg (23.1 lb) compared with 3.6 kg (7.9 lb) with the higher dulaglutide dose (P<0.001), according to Liana Billings, MD, of the University ...

"The analysis shows that in the SURPASS-4 trial, approximately 80% of individuals who were treated with tirzepatide and who reached an A1c of 6.5% or weight loss > 10% at 52 weeks retained ...

In the SURPASS clinical trial program (SURPASS 1-5; ClinicalTrials.gov; Identifiers: NCT03954834, NCT03987919, NCT03882970, NCT03730662, NCT04039503), the effect of tirzepatide for reducing ...

In SURPASS‑4, the levels had to be 58 mmol/mol (7.5%) or more to 91 mmol/mol (10.5%) or less. People also had to have had a stable weight for 3 months, and a BMI of 25 kg/m 2 or more in SURPASS‑2, -3 ...

Meta-analysis results revealed that Tirzepatide (all three doses – 5, 10, and 15 mg) significantly outperformed both long- and ultra-long-lasting insulin supplements, reducing weight in T2D ...

Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials.